The end-stage renal disease therapeutics market in the seven key markets of the US, the UK, Germany, France, Italy, Spain and Japan was worth $2.03 billion in 2011.
The end-stage renal disease therapeutics market has been estimated to grow at a compound annual growth rate (CAGR) of 0.8% to 2019, reaching a market value of $2.16 billion.
The rising incidence of kidney disease due to increasing obesity, high blood pressure and diabetes is forming a gigantic market for new end-stage renal disease treatments.
No targeted therapy currently exists to slow down disease progression in patients with end-stage renal disease, who currently rely on expensive options such as dialysis or kidney transplant.
This gap in the end-stage renal disease therapeutics market could therefore provide opportunities for pharmaceutical companies able to develop drugs to directly treat renal damage and slash healthcare spending.
A new molecule offering disease-modifying therapy to treat the underlying causes of end-stage renal disease would reduce patient dependence on dialysis and transplantation, transforming the lives of individuals living with renal diseases.
Currently, no drugs are able to restore normal kidney function, but the end-stage renal disease therapeutics market eagerly waits for a revolutionary drug able to delay disease progression.
For more information on the end-stage renal disease therapeutics market, see the latest research: End-Stage Renal Disease Therapeutics Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.